Cargando…

Knowledge of liver fibrosis stage among adults with NAFLD/NASH improves adherence to lifestyle changes

BACKGROUND & AIMS: Though lifestyle interventions can reverse disease progression in people with non‐alcoholic fatty liver disease/non‐alcoholic steatohepatitis (NAFLD/NASH), unawareness about disease severity might compromise behavioural changes. Data from this first international cross‐section...

Descripción completa

Detalles Bibliográficos
Autores principales:	Carrieri, Patrizia, Mourad, Abbas, Marcellin, Fabienne, Trylesinski, Aldo, Calleja, José Luis, Protopopescu, Camelia, Lazarus, Jeffrey V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Liver Disease and Public Health
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9310954/ https://www.ncbi.nlm.nih.gov/pubmed/35220673 http://dx.doi.org/10.1111/liv.15209

Ejemplares similares

Natural History of NAFLD/NASH
por: Ekstedt, Mattias, et al.
Publicado: (2017)

Prevalence estimation of significant fibrosis because of NASH in Spain combining transient elastography and histology
por: Calleja, José L., et al.
Publicado: (2022)

Serum coding and non‐coding RNAs as biomarkers of NAFLD and fibrosis severity
por: Di Mauro, Stefania, et al.
Publicado: (2019)

Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis
por: McPherson, Stuart, et al.
Publicado: (2017)

Metabolic regulation of hepatic PNPLA3 expression and severity of liver fibrosis in patients with NASH
por: Bruschi, Francesca V., et al.
Publicado: (2020)

Lifestyle modification in NAFLD/NASH: Facts and figures
por: Hallsworth, Kate, et al.
Publicado: (2019)

Imaging biomarkers of NAFLD, NASH, and fibrosis
por: Ajmera, Veeral, et al.
Publicado: (2021)

Non‐alcoholic fatty liver disease and the risk of fibrosis in Italian primary care services: GPS‐NAFLD Study
por: Miele, Luca, et al.
Publicado: (2022)

Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models
por: Jain, Mukul R., et al.
Publicado: (2017)

Serum aromatic and branched‐chain amino acids associated with NASH demonstrate divergent associations with serum lipids
por: de Mello, Vanessa D., et al.
Publicado: (2020)

PPAR‐γ‐induced changes in visceral fat and adiponectin levels are associated with improvement of steatohepatitis in patients with NASH
por: Gastaldelli, Amalia, et al.
Publicado: (2021)

Risk of hepatic and extrahepatic cancer in NAFLD: A population‐based cohort study
por: Björkström, Karl, et al.
Publicado: (2022)

Patient-reported outcomes with direct-acting antiviral treatment for hepatitis C in West and Central Africa (TAC ANRS 12311 trial)
por: Marcellin, Fabienne, et al.
Publicado: (2022)

Early Intervention With Live Donor Liver Transplantation Reduces Resource Utilization in NASH: The Toronto Experience
por: Barbas, Andrew S., et al.
Publicado: (2017)

Liver transplantation for NAFLD cirrhosis: Age and recent coronary angioplasty are major determinants of survival
por: Villeret, François, et al.
Publicado: (2022)

NAFLD is related to Post‐prandial Triglyceride‐enrichment of HDL Particles in Association with Endothelial and HDL Dysfunction
por: Verwer, Bart J., et al.
Publicado: (2020)

Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD
por: Bazick, Jessica, et al.
Publicado: (2015)

The role of the microbiome in NAFLD and NASH
por: Kolodziejczyk, Aleksandra A, et al.
Publicado: (2018)

Noninvasive Diagnosis of NAFLD and NASH
por: Piazzolla, Valeria Annarita, et al.
Publicado: (2020)

Disease burden and economic impact of diagnosed non‐alcoholic steatohepatitis in five European countries in 2018: A cost‐of‐illness analysis
por: Schattenberg, Jörn M., et al.
Publicado: (2021)

A minority of somatically mutated genes in pre‐existing fatty liver disease have prognostic importance in the development of NAFLD
por: Mann, Jake P., et al.
Publicado: (2022)

Non-invasive markers of liver fibrosis in fatty liver disease are unreliable in people of South Asian descent
por: De Silva, Sampath, et al.
Publicado: (2018)

Comparison of various strategies to define the optimal target population for liver fibrosis screening: A population‐based cohort study
por: Åberg, Fredrik, et al.
Publicado: (2022)

Evolving Role for Pharmacotherapy in NAFLD/NASH
por: Attia, Suzanna L., et al.
Publicado: (2020)

A continuous-time Markov chain model of fibrosis progression in NAFLD and NASH
por: Meyer, Lyndsey F., et al.
Publicado: (2023)

Ultra‐high‐field magnetic resonance spectroscopy in non‐alcoholic fatty liver disease: Novel mechanistic and diagnostic insights of energy metabolism in non‐alcoholic steatohepatitis and advanced fibrosis
por: Traussnigg, Stefan, et al.
Publicado: (2017)

Multicenter Validation Study of a Diagnostic Algorithm to Detect NASH and Fibrosis in NAFLD Patients With Low NAFLD Fibrosis Score or Liver Stiffness
por: Liebig, Stephanie, et al.
Publicado: (2019)

Comorbidities and healthcare costs and resource use of patients with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) in the Japan medical data vision database
por: Terai, Shuji, et al.
Publicado: (2021)

Adherence to opioid agonist therapy predicts uptake of direct-acting antivirals in people who use drugs: results from the French national healthcare database (the ANRS FANTASIO study)
por: Rolland, Benjamin, et al.
Publicado: (2022)

MAFLD/NAFLD Biopsy-Free Scoring Systems for Hepatic Steatosis, NASH, and Fibrosis Diagnosis
por: Segura-Azuara, Nancy de los Ángeles, et al.
Publicado: (2022)

Current and future pharmacological therapies for NAFLD/NASH
por: Sumida, Yoshio, et al.
Publicado: (2017)

Diet and exercise in NAFLD/NASH: Beyond the obvious
por: Semmler, Georg, et al.
Publicado: (2021)

NAFLD and NASH in HCV Infection: Prevalence and Significance in Hepatic and Extrahepatic Manifestations
por: Adinolfi, Luigi Elio, et al.
Publicado: (2016)

Progressive alcohol‐related liver fibrosis is characterised by imbalanced collagen formation and degradation
por: Thiele, Maja, et al.
Publicado: (2021)

Mechanisms of fibrosis in acute liver failure
por: He, Yingli, et al.
Publicado: (2015)

Role of NLRP3 Inflammasome in the Progression of NAFLD to NASH
por: Wan, Xingyong, et al.
Publicado: (2016)

Depression and Cognitive Impairment—Extrahepatic Manifestations of NAFLD and NASH
por: Colognesi, Martina, et al.
Publicado: (2020)

Current Options and Future Directions for NAFLD and NASH Treatment
por: Zhang, Chunye, et al.
Publicado: (2021)

Improved pathology reporting in NAFLD/NASH for clinical trials
por: Langford, Caitlin Rose, et al.
Publicado: (2022)

Emerging Role of Nuclear Receptors for the Treatment of NAFLD and NASH
por: Welch, Ryan D., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_cdlg5fhndmlq5h7lc7nbc33pqo